Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is the entire market collapsing vs any Mydecine's shortfalls. I am in about 25 stocks and only one was green today. The NASDAQ was down around 667 pts at some stage I read. Even MindMed has fallen to below $3.00 again which no-one ever expected. It is dodgy manipulation as a backlash to the Reddit crowd I am hearing (speculatively).
All this good news and the sp keeps sinking
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
Post published:March 1, 2021
Post category:Press Release
DENVER, March 01, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma company in the life sciences category committed to the research and development, production, and acceptance of alternative nature-sourced medicine for mainstream use, has completed the world’s first international legal export of dried psilocybin mushrooms.
In December 2020, the Company announced the completion of its first commercial harvest of 20 kilograms (44 lbs) of psilocybin mushrooms at a private mycology-focused research and cultivation facility in Jamaica. The first shipment of the harvest has now been received at Mydecine’s Canadian Current Good Manufacturing Practice (CGMP) facility, which has a Health Canada Schedule 1 Dealer’s License attached to it, allowing for legal import/export, research and development, cultivation, product development, and commercial sale of active psychedelic medicinal compounds.
“This milestone is significant to our 2021 goals as we are now able to access a quality source of much needed product for both our own research purposes, as well as provide CGMP naturally-derived psilocybin to sell and transfer to other licensed research facilities around the globe. Our team has spent significant time working with various government agencies to create and develop sound protocols to ensure a smooth flow of biomass that is in full compliance with all federal laws. This is the first and only solidified commercial supply chain of psilocybin mushrooms and we believe this supply chain will open up many doors to potentially collaborate and participate in initiatives that we find potentially promising,” said Joshua Bartch, CEO and Chairman of Mydecine. “We have made significant progress towards having the first IND number on a 99.9% pure psilocybin product that the synthetic form mimics. We believe our natural-sourced psilocybin, that is both significantly less costly and more efficient than the synthetic form, will prove to be a better overall option to meet the current market demand as well as voids any and all potential patent claims. This marks a milestone of fulfilling on the promise of creating a fully vertical and uninterrupted global supply chain.”
“In the most potent psychedelic mushrooms, psilocybin is typically only around 1% of its total mass. This means that as much as 99% of the mushroom is composed of vegetative matter plus other potential active medicinal compounds. At our lab, we have already discovered multiple other active compounds separate from psilocybin and psilocin from just our initial psychedelic mushroom analysis. Based upon our preliminary studies, we believe that this could have more effective results than just single-molecule synthetic psilocybin. This supply chain will give us unrestrictive scalable access including numerous types of unique psychedelic mushroom species native to Jamaica. This should significantly increase our research and development and production efforts with some of the best types of mushrooms that we know of,” said Damon Michaels, Mydecine’s Co-Founder and Chief Operating Officer.
He continued, “Throughout history we have seen many historical instances involving the use of psychedelic medicine, more so the use of psychedelic mushrooms to be used as safe and effective therapeutic medicine to help improve mental injuries or expand one’s overall consciousness. Today we are able to take this ancient form of holistic medicine and pair it with modern technology to better understand its active ingredients and how they specifically interact with the brain and body to produce the best, most controllable and beneficial results possible. For Mydecine to be able to create the world’s first legal global supply chain of nature-sourced psilocybin to not only meet its own needs, but to supply to other licensed research organizations, universities, and healthcare facilities around the world, we hope to finally break the barrier of stigma and help people obtain mainstream access to this sacred medicine and turn it back into a traditional therapy.”
About Mydecine Innovations Group
Mydecine Innovations Group™ (CSE: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.
At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.
Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.
Mydecine Innovations Group Media Contacts
Anne Donohoe / Nick Opich
KCSA Strategic Communications
adonohoe@kcsa.com / nopich@kcsa.com
212-896-1265 / 212-896-1206
On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com
Corp Communications:
Charles Lee, Investor Relations
corp@mydecineinc.com
+1 720-277-9879
For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.
Looks to be turning back up. Nice news today as well. This is a great long term hold for those with some patience.
Tramp on a kebab. Lol
All over this like a Tramp on a dropped Khebab. For how long begs the question. MindMed rules big time however, there is room for certain other promising players like Mydecine IMO.
Just whoring around a bit see how things go. I figure they're good enough for Cannacord to invest in, good enough for me. I also like a couple cannabis canna in as well. They're pretty smart Canadians.
You playing here bro?
I’m a buyer here in the low .40 area. We’re churning through the recent placement of shares but if this volume keeps up we’ll clear the overhang by next week. I see .75+ on this next leg up.
Pretty quite here. Best get in before it's too late?
Morning everyone,
I'm just doing my DD on this company. I see that they were once a cbd company that acquired a mushroom company and changed ticker symbol. Are they still a CBD company or are they now a pure mushroom company? I'm trying to do research on the structure of this company but I only see the mushroom company website. the old new leaf brands website is currently down
thanks for the help
Starting a position down here in the low .40s.
Don't sleep on this one. A pop is coming.
I agree. Definitely good news. Thanks again for the input.
Yea. It’ll dip but overall it’s good news. Cannacord Investor backing
Thank you. I saw where there was some type of 20,000,000 share offering at .50
Halted on Canadian side pending news
What's happening here? I see no trading activity at all this morning. Is it me, am I missing something here? Thanks in advance for any comments.
Another point to note is the Horizons psychedelic ETF goes live on Friday. I gotta imagine that brings more juice to the sector
Agreed. I'll hold on to a core position a while and see what happens - along with a few others in the sector
Dollar land. Wait until the trials news hits
This is not like the hemp/cowboy stocks. They have real products not just dreams. I have a very small pos. But this is the kind of stockyou keep. And not trade. Slowly this will move up. And one day you look, and its 5$. Safer then under your matres.
Let's go!! $$$
.35 Mydecine Innovations Group™? (CSE: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality.
https://www.mydecine.com/#portfolio-copy
Without actually looking, I'd say 1) cool off after parabolic runs from LKYSF MMEDF etc.. 2) pre IPO / paper hitting.... 3) retails panic + inexperienced investors (I know multiple ppl who bought their first stock recently in psychedelics - FOMO from missing cannabis)
Just some thoughts... I'm on the sidelines mostly waiting for a turn around.
GL!
Wonder why shrooms stock are dipping
Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
DENVER, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has engaged ethica CRO ("ethica CRO"), a full-service Contract Research Organization (“CRO”) that conducts and manages ethical clinical research on drugs, biologics, medical devices and more, as the contract research organization ("CRO") for its upcoming Phase 2A PTSD clinical trials.
ethica CRO is a full-service, global CRO that provides drug development services to biopharmaceutical companies in clinical trials. ethica CRO provides a complete range of clinical study management and biometrics services for clinical research phases I through IV. Since its inception in 2002, ethica CRO has dedicated its efforts to bring a new dimension to the clinical research industry, the ethical dimension, focused on integrating research participants as partners in research rather than simply subjects of research. ethica CRO was the first CRO in the world to be accredited for its human research protection program in 2006 and is the only CRO in the world to have achieved accreditation from three different accrediting bodies
"We are excited to bring on a high-caliber partner in ethica CRO, which has extensive expertise in managing clinical studies to the highest standards of ethical and clinical practice, as the CRO for Mydecine’s upcoming Phase 2A PTSD clinical trials," commented Josh Bartch, CEO of Mydecine Innovations Group. "Engaging ethica CRO is one of the key pieces of our preparations as we explore how the brain responds to psychedelics and develop a better understanding of the biological underpinnings created by the psychedelic experience. We maintain that their insight and unparalleled experience in trials of this nature provide the best opportunity to further drive Mydecine's clinical development. We believe that with ethica CRO’s deep clinical experience, and through our achievements in trial preparation, we are optimally positioned for our upcoming Phase 2A PTSD clinical trials in Veterans in Canada and the United States."
ethica CRO’s dedication to research participant protection made it a partner of choice for the Canadian Department of National Defence. ethica CRO has participated in a series of clinical development programs with the Canadian DND and various NATO allies, most notably synthetic cannabinoids in the treatment of PTSD, injectable antidotes to chemical weapons, and skin decontamination kits for neutralizing chemical warfare agents.
“Psychedelics and psychedelic-assisted therapies are rapidly proving to be some of the most exciting developments in mental health treatment in decades,” said Murray Jensen, Managing Director of ethica CRO. “Mydecine’s ambitious approach to researching and tackling the mental health challenges facing veterans and other frontline workers aligns with our values and mission at ethica and we are excited to hit the ground running with the Mydecine team as they push forward in their pursuit to transform mental health.”
Mydecine’s international Phase 2A clinical trials will focus on psilocybin-assisted psychotherapy to treat chronic PTSD in veterans and EMS personnel. The research will take place at Leiden University Medical Centre in the Netherlands; the University of Western Ontario; and the University of Alberta, with other clinical sites on the horizon in the USA, Europe, and Australia. Through these trials, Mydecine hopes to establish the safety and efficacy of psychedelic administered psychotherapy in a safe and supervised setting, utilizing strict protocols approved by research ethics boards and build upon the body of work that has led to psilocybin-assisted psychotherapy to receive “breakthrough” status by the FDA.
https://www.otcmarkets.com/stock/MYCOF/news/story?e&id=1770933
MYCOF===Looking like a huge potential upside here!=$$$$
I hope you own mmedf as well....
Nice comeback from the dip this morning!
Nice close after a dip below .40
HUGE.....Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials https://finance.yahoo.com/news/mydecine-innovations-group-engages-propharma-123000101.html
Nice shake. Moving back up!
Next resistance is .60 If we blow past that, here comes $1.00
BOOMTIME!!! Just hit .50!
Setting up a new brokerage to get in this beast !
WOW....opens at .44! I have not researched SHRMF. My favorite sector plays are MYCOF and MMEDF
Looks like we blow past .40 today. On a separate note, my other big holding, MindMed, has great news and look to blow past $4 today. This sector is HOT!
TD Ameritrade with no issues
E*TRADE won’t let me buy because caveat emptor. Any way around it ? I want to get in
Previous high will be taken out soon.
Sounds like someone wants cheaper shares :)
Canadian SCAM will be suspended soon!!!
TOXIC RINSE!!!
ROFLMAO
Yes......I/We need to invest in this sector......
Followers
|
72
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1209
|
Created
|
09/24/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |